22 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 22 of 22 clinical reviews.
Structured exercise programs reduce OSA severity by 25-50% even without weight loss. Review the evidence on aerobic, resistance, and oropharyngeal training protocols for AHI reduction.
A board-reviewed annual evaluation checklist for obstructive sleep apnea (OSA): AHI targets, CPAP adherence review, weight management, comorbidity screening, and updated 2024 treatment options including tirzepatide.
A complete walkthrough of the OSA diagnostic algorithm: screening tools, home vs. Lab sleep testing, AHI thresholds, severity classification, and first-line treatment options including CPAP, weight loss, and tirzepatide (Zepbound).
A deep dive into the latest OSA mechanism research: loop gain, arousal threshold, upper-airway muscle dysfunction, hypoxic signaling, and GLP-1 pathway discoveries that are reshaping treatment strategy.
A look at emerging OSA research, including tirzepatide's FDA-approved role, positive airway pressure, endotypes, devices, and diagnostic advances.
A guide to first-line OSA treatment decisions, covering CPAP, positional therapy, oral appliances, weight-loss interventions including tirzepatide, and surgery, with AHI-based thresholds and society guideline citations.
An evidence-based overview of obstructive sleep apnea global prevalence, regional trends, risk factors, and clinical burden, prepared by the HealthRX.com Editorial Team.
How OSA diagnosis and first-line treatment differ across pregnant women, children, older adults, people with obesity, and people with cardiovascular disease or diabetes, including where tirzepatide and CPAP fit and where the evidence is still incomplete.
A guide to identifying, evaluating, and enrolling in the right OSA clinical trial, covering eligibility, trial phases, key studies like SURMOUNT-OSA, and how GLP-1 therapies are reshaping OSA research.
A comprehensive clinical history of obstructive sleep apnea treatment from tracheotomy in the 1960s through CPAP, oral appliances, surgery, and the emerging GLP-1 era, with primary-source citations throughout.
A complete guide to preparing for your first OSA appointment, what to track, what questions to ask, and what diagnostic and treatment options to expect, including CPAP, weight-loss therapy, and FDA-approved tirzepatide.
A guide to stopping CPAP, positional therapy, or GLP-1 treatment for OSA safely, including when re-testing is required, what guidelines say, and how weight loss changes the calculus.
How partners and family members can recognize OSA symptoms, support CPAP adherence, encourage weight-loss treatment, and help a loved one get diagnosed and stay on track.
Learn exactly when OSA treatment has failed, what AHI thresholds, symptom persistence, and adherence gaps define failure, and which evidence-based next steps apply.
A guide on obstructive sleep apnea covering diagnosis, treatment options including Zepbound, CPAP, and surgery, plus clear signals that your care plan warrants a second opinion.
Obstructive sleep apnea rarely travels alone. Learn which comorbidities overlap most with OSA, how they interact, and what the clinical evidence says about managing them together.
Obstructive sleep apnea has a strong genetic component. Learn how family history, inherited craniofacial traits, and specific gene variants increase OSA risk, and what screening steps to take.
Evidence-based nutrition, weight-management, and lifestyle interventions for obstructive sleep apnea (OSA), including dietary patterns, GLP-1 receptor agonists, exercise protocols, and positional therapy.
Black, Hispanic, Asian, and Native American populations face higher OSA prevalence, later diagnosis, and worse outcomes than white patients. Learn what drives these gaps and what clinicians can do.
Evidence-based OSA treatment algorithm organized by line of therapy, from CPAP and oral appliances to tirzepatide and surgical options, with AHI-based staging and trial data.
Sleep apnea follow-up care: CPAP check at 30 days, clinical review at 3 months, then every 6-12 months with annual cardiometabolic screening.
Endocrine Society advises against testosterone therapy in untreated severe OSA. See this rule alongside ADA, AACE, AASM, and USPSTF guidance compared.